Modulation of the gait deficit in arthritic rats by infusions of muscimol and bicuculline

Shabana U. Simjee; Barbara J. Pleuvry; Paul Coulthard

doi:10.1016/j.pain.2004.02.022

Modulation of the gait deficit in arthritic rats by infusions of muscimol and bicuculline

Shabana U. Simjee, Barbara J. Pleuvry, Paul Coulthard

Research output: Contribution to journal › Article › peer-review

Abstract

Gait analysis in the adjuvant-induced arthritic rat model of chronic pain was used to examine the role of GABAA receptors in the development of pain. Drug solutions were administered continuously at 5±0.75 μl/h for 14 days via Alzet® osmotic pumps (2ML2) placed under the skin of the back. The GABAA receptor agonist, muscimol, produces a dose-dependent reversal of the gait deficits seen in arthritic rats without reducing the tibiotarsal joints inflammatory edema or the histological picture of joint erosion and inflammation. The higher infusion rate for muscimol, 20 μg/h, caused the gait for the arthritic rats to be indistinguishable from that of normal non-arthritic rats. In normal, non-arthritic rats, muscimol did not show any effect on gait. The GABAA receptor antagonist bicuculline showed small but significant exacerbation of stride length (P

Original language	English
Pages (from-to)	453-460
Number of pages	7
Journal	Pain
Volume	109
Issue number	3
DOIs	https://doi.org/10.1016/j.pain.2004.02.022
Publication status	Published - Jun 2004

Keywords

Arthritis
Bicuculline
Chronic pain
Muscimol

Access to Document

10.1016/j.pain.2004.02.022

Cite this

@article{761bd4b7bf9c446ea60dc02ec328f1e5,

title = "Modulation of the gait deficit in arthritic rats by infusions of muscimol and bicuculline",

abstract = "Gait analysis in the adjuvant-induced arthritic rat model of chronic pain was used to examine the role of GABAA receptors in the development of pain. Drug solutions were administered continuously at 5±0.75 μl/h for 14 days via Alzet{\textregistered} osmotic pumps (2ML2) placed under the skin of the back. The GABAA receptor agonist, muscimol, produces a dose-dependent reversal of the gait deficits seen in arthritic rats without reducing the tibiotarsal joints inflammatory edema or the histological picture of joint erosion and inflammation. The higher infusion rate for muscimol, 20 μg/h, caused the gait for the arthritic rats to be indistinguishable from that of normal non-arthritic rats. In normal, non-arthritic rats, muscimol did not show any effect on gait. The GABAA receptor antagonist bicuculline showed small but significant exacerbation of stride length (P",

keywords = "Arthritis, Bicuculline, Chronic pain, Muscimol",

author = "Simjee, {Shabana U.} and Pleuvry, {Barbara J.} and Paul Coulthard",

year = "2004",

month = jun,

doi = "10.1016/j.pain.2004.02.022",

language = "English",

volume = "109",

pages = "453--460",

journal = "Pain",

issn = "0304-3959",

publisher = "Lippincott Williams & Wilkins",

number = "3",

}

TY - JOUR

T1 - Modulation of the gait deficit in arthritic rats by infusions of muscimol and bicuculline

AU - Simjee, Shabana U.

AU - Pleuvry, Barbara J.

AU - Coulthard, Paul

PY - 2004/6

Y1 - 2004/6

N2 - Gait analysis in the adjuvant-induced arthritic rat model of chronic pain was used to examine the role of GABAA receptors in the development of pain. Drug solutions were administered continuously at 5±0.75 μl/h for 14 days via Alzet® osmotic pumps (2ML2) placed under the skin of the back. The GABAA receptor agonist, muscimol, produces a dose-dependent reversal of the gait deficits seen in arthritic rats without reducing the tibiotarsal joints inflammatory edema or the histological picture of joint erosion and inflammation. The higher infusion rate for muscimol, 20 μg/h, caused the gait for the arthritic rats to be indistinguishable from that of normal non-arthritic rats. In normal, non-arthritic rats, muscimol did not show any effect on gait. The GABAA receptor antagonist bicuculline showed small but significant exacerbation of stride length (P

AB - Gait analysis in the adjuvant-induced arthritic rat model of chronic pain was used to examine the role of GABAA receptors in the development of pain. Drug solutions were administered continuously at 5±0.75 μl/h for 14 days via Alzet® osmotic pumps (2ML2) placed under the skin of the back. The GABAA receptor agonist, muscimol, produces a dose-dependent reversal of the gait deficits seen in arthritic rats without reducing the tibiotarsal joints inflammatory edema or the histological picture of joint erosion and inflammation. The higher infusion rate for muscimol, 20 μg/h, caused the gait for the arthritic rats to be indistinguishable from that of normal non-arthritic rats. In normal, non-arthritic rats, muscimol did not show any effect on gait. The GABAA receptor antagonist bicuculline showed small but significant exacerbation of stride length (P

KW - Arthritis

KW - Bicuculline

KW - Chronic pain

KW - Muscimol

U2 - 10.1016/j.pain.2004.02.022

DO - 10.1016/j.pain.2004.02.022

M3 - Article

SN - 0304-3959

VL - 109

SP - 453

EP - 460

JO - Pain

JF - Pain

IS - 3

ER -

Modulation of the gait deficit in arthritic rats by infusions of muscimol and bicuculline

Abstract

Keywords

Access to Document

Fingerprint

Cite this